Efocipegtrutide - Hanmi Pharmaceutical
Alternative Names: GLP-1/GIP/glucagon triagonist - Hanmi Pharmaceutical; HM-15211; LAPS-triple agonistLatest Information Update: 28 Jul 2024
At a glance
- Originator Hanmi Pharmaceutical
- Class Antidementias; Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Antiparkinsonians; Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Preclinical Idiopathic pulmonary fibrosis
- No development reported Hepatic fibrosis; Non-alcoholic fatty liver disease
- Discontinued Alzheimer's disease; Dyslipidaemias; Multiple sclerosis; Obesity; Parkinson's disease; Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Non-alcoholic-fatty-liver-disease in USA (SC)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Hepatic-fibrosis in South Korea
- 10 Nov 2023 Pharmacodynamics data from a preclinical trial in Liver Injury presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)